Showing 850 results
-
Media Release /- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
-
Media Release /- elevateMS study allows researchers to collect sensor-based movement data and symptoms directly from participants without the need for clinic visits- Study aims to improve understanding of daily…
-
Media Release /AMG 334 (erenumab) is an investigational therapy with a novel mechanism of action for migraine prevention for patients with high unmet needMigraine is associated with pain, disability and nearly $25…
-
Media Release /- Kiss This 4 MBC goes beyond raising awareness of metastatic breast cancer to generate an increase in public support and research funds for the estimated 155,000 people living with this disease in…
-
Media Release /- Cosentyx® (secukinumab) is the first and only fully human IL-17A antagonist to show sustained skin clearance rates at 5 years in Phase III in psoriasis(1)- Landmark data show that PASI 90 and PASI…
-
Media Release /- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
-
Media Release /
Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day
- "Hope" is inspired by the psoriasis community and Lauper's own experience living with the disease- Song and music video are available to stream at SEEMEtoknow.com- An estimated 7.5 million people… -
Media Release /- Nearly 70% of patients maintained platelet counts of ≥30×10[9]/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding- More than one-third of patients permanently…
-
Media Release /Consumer education campaign highlights the important role of vision in giving "everyday" athletes an invisible edge on and off the fieldNew survey uncovers that clear eyesight is more important than…
-
Media Release /- Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study(1)- PsA can lead to reduced mobility…
